SHARE

Sanofi Q1 boosted by Dupixent growth as vaccines and pipeline face pressure

The pharmaceutical group reported Q1 sales of €10.5bn, with Dupixent up 31% to €4.2bn driving growth. Vaccines rose modestly despite policy headwinds, while Sanofi continues reshaping its consumer healthcare exposure following the 2025 Opella spin-off.

Certification Note

Certified B Corporation” is a trademark licensed by B Lab, a private non-profit organization, to companies like ours that have successfully completed the B Impact Assessment (“BIA”) and therefore meet the requirements set by B Lab for social and environmental performance, accountability, and transparency. It is specified that B Lab is not a conformity assessment body as defined by Regulation (EU) No 765/2008, nor is it a national, European, or international standardization body as per Regulation (EU) No 1025/2012. The criteria of the BIA are distinct and independent from the harmonized standards resulting from ISO norms or other standardization bodies, and they are not ratified by national or European public institutions.